Publications

  1. Ailawadhi S, Kardosh A, Yang D, Cozen W, Patel G, Alamgir MA, Chanan-Khan AA. Outcome Disparities among Ethnic Subgroups of Waldenstrom's Macroglobulinemia: A Population-Based Study. Oncology. 2014 Jun 04; 86(5-6):253-62.
    View PubMed
  2. Paulus A, Masood A, Miller KC, Khan AN, Akhtar D, Advani P, Foran J, Rivera C, Roy V, Colon-Otero G, Chitta K, Chanan-Khan A. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. Br J Haematol. 2014 Apr; 165(1):78-88. Epub 2014 Jan 27
    View PubMed
  3. Chitta KS, Khan AN, Ersing N, Swaika A, Masood A, Paulus A, Qadeer A, Advani P, Sher T, Miller KC, Lee K, Chanan-Khan AA. Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells. Leuk Lymphoma. 2014 Mar; 55(3):652-61. Epub 2013 Jul 01.
    View PubMed
  4. Lazaridis KN, McAllister TM, Babovic-Vuksanovic D, Beck SA, Borad MJ, Bryce AH, Chanan-Khan AA, Ferber MJ, Fonseca R, Johnson KJ, Klee EW, Lindor NM, McCormick JB, McWilliams RR, Parker AS, Riegert-Johnson DL, Rohrer Vitek CR, Schahl KA, Schultz C, Implementing individualized medicine into the medical practice. Am J Med Genet C Semin Med Genet. 2014 Mar; 166C(1):15-23. Epub 2014 Mar 10.
    View PubMed
  5. Paulus A, Chitta K, Akhtar S, Personett D, Miller KC, Thompson KJ, Carr J, Kumar S, Roy V, Ansell SM, Mikhael JR, Dispenzieri A, Reeder CB, Rivera CE, Foran J, Chanan-Khan A. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia. Br J Haematol. 2014 Feb; 164(3):352-65. Epub 2013 Nov 17.
    View PubMed
  6. Ansell SM, Hodge LS, Secreto FJ, Manske M, Braggio E, Price-Troska T, Ziesmer S, Li Y, Johnson SH, Hart SN, Kocher JP, Vasmatzis G, Chanan-Kahn A, Gertz M, Fonseca R, Dogan A, Cerhan JR, Novak AJ. Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma. Blood Cancer J. 2014; 4:e183. Epub 2014 Feb 14.
    View PubMed
  7. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013 Dec 19; 122(26):4172-81. Epub 2013 Oct 21.
    View PubMed
  8. Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec; 27(12):2351-6. Epub 2013 May 14.
    View PubMed
  9. Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec; 27(12):2351-6. Epub 2013 May 14.
    View PubMed
  10. Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, Wegener WA, Goldenberg DM. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol. 2013 Nov; 163(4):478-86. Epub 2013 Sep 25.
    View PubMed
  11. Fernandez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013 Apr; 27(4):780-91. Epub 2012 Nov 21
    View PubMed
  12. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013 Apr; 88(4):360-76.
    View PubMed
  13. Chitta KS, Paulus A, Ailawadhi S, Foster BA, Moser MT, Starostik P, Masood A, Sher T, Miller KC, Iancu DM, Conroy J, Nowak NJ, Sait SN, Personett DA, Coleman M, Furman RR, Martin P, Ansell SM, Lee K, Chanan-Khan AA. Development and characterization of a novel human Waldenstrom macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenstrom Macroglobulinemia 1. Leuk Lymphoma. 2013 Feb; 54(2):387-96. Epub 2012 Aug 27.
    View PubMed
  14. Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar SV, Dispenzieri A, Lacy MQ. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013; 3:e143. Epub 2013 Sep 06.
    View PubMed
  15. Razavi P, Rand KA, Cozen W, Chanan-Khan A, Usmani S, Ailawadhi S. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J. 2013; 3:e121. Epub 2013 Jun 28
    View PubMed
  16. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 4; 120(14):2817-25. Epub 2012 Jul 25.
    View PubMed
  17. Chanan-Khan AA, Lonial S, Weber D, Borrello I, Foa R, Hellmann A, Dimopoulos M, Swern AS, Knight R. Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients >/=65 years old with relapsed or refractory multiple myeloma. Int J Hematol. 2012 Aug; 96(2):254-62. Epub 2012 Jul 03.
    View PubMed
  18. Blickwedehl J, Olejniczak S, Cummings R, Sarvaiya N, Mantilla A, Chanan-Khan A, Pandita TK, Schmidt M, Thompson CB, Bangia N. The proteasome activator PA200 regulates tumor cell responsiveness to glutamine and resistance to ionizing radiation. Mol Cancer Res. 2012 Jul; 10(7):937-44. Epub 2012 May 01.
    View PubMed
  19. Kasyapa CS, Sher T, Chanan-Khan AA. Multiple myeloma and immunomodulation: regulating the regulatory cells. Leuk Lymphoma. 2012 Jul; 53(7):1253-4. Epub 2012 Apr 03.
    View PubMed
  20. Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T, Chanan-Khan A. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012 Jul; 158(1):91-8. Epub 2012 Apr 26.
    View PubMed
  21. Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D, Wood M, Masood A, Lee K, Chanan-Khan AA. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol. 2012 Jul-Aug; 10(4):155-9. Epub 2012 Jan 04.
    View PubMed
  22. Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, Masood A, Neuwirth R, Lee KP, Chanan-Khan A. Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012 Jun; 53(6):1174-82. Epub 2011 Dec 6
    View PubMed
  23. Rodgers GM 3rd, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB 3rd. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2012 May; 10(5):628-53.
    View PubMed
  24. Chanan-Khan AA, San Miguel JF, Jagannath S, Ludwig H, Dimopoulos MA. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res. 2012 Apr 15; 18(8):2145-63. Epub 2012 Feb 10.
    View PubMed
  25. Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP, Chanan-Khan A. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br J Haematol. 2012 Apr; 157(1):59-66. Epub 2011 Dec 15
    View PubMed
  26. Smonskey MT, Block AW, Deeb G, Chanan-Khan AA, Bernstein ZP, Miller KC, Wallace PK, Starostik P. Monoallelic and biallelic deletions of 13q14.3 in chronic lymphocytic leukemia: FISH vs miRNA RT-qPCR detection. Am J Clin Pathol. 2012 Apr; 137(4):641-6.
    View PubMed
  27. Wendtner CM, Hillmen P, Mahadevan D, Buhler A, Uharek L, Coutre S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Mar; 53(3):417-23. Epub 2011 Nov 15.
    View PubMed
  28. Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T, Swaika A, Wallace PK, Mashtare TL Jr, Wilding G, Lee K, Czuczman MS, Borrello I, Bangia N. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol. 2011 Nov; 155(4):457-67. Epub 2011 Oct 20.
    View PubMed
  29. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1146-83.
    View PubMed
  30. Nair JR, Carlson LM, Koorella C, Rozanski CH, Byrne GE, Bergsagel PL, Shaughnessy JP Jr, Boise LH, Chanan-Khan A, Lee KP. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol. 2011 Aug 1; 187(3):1243-53. Epub 2011 Jun 29.
    View PubMed
  31. Rozanski CH, Arens R, Carlson LM, Nair J, Boise LH, Chanan-Khan AA, Schoenberger SP, Lee KP. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J Exp Med. 2011 Jul 4; 208(7):1435-46. Epub 2011 Jun 20.
    View PubMed
  32. Sher T, Ailawadhi S, Miller KC, Manfredi D, Wood M, Tan W, Wilding G, Czuczman MS, Hernandez-Ilizaliturri FJ, Hong F, Sood R, Soniwala S, Lawrence W, Jamshed S, Masood A, Iancu D, Lee K, Chanan-Khan A. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol. 2011 Jul; 154(1):104-10. Epub 2011 May 09.
    View PubMed
  33. Richardson PG, Chanan-Khan AA, Lonial S, Krishnan AY, Carroll MP, Alsina M, Albitar M, Berman D, Messina M, Anderson KC. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol. 2011 Jun; 153(6):729-40. Epub 2011 Apr 28.
    View PubMed
  34. Advani PP, Paulus A, Masood A, Sher T, Chanan-Khan A. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2011 Jun; 7(6):765-74. Epub 2011 Apr 27.
    View PubMed
  35. Chanan-Khan A, Miller KC, Lawrence D, Padmanabhan S, Miller A, Hernandez-Illatazurri F, Czuczman MS, Wallace PK, Zeldis JB, Lee K. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2011 May 15; 117(10):2127-35. Epub 2010 Nov 29.
    View PubMed
  36. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksac M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S, Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011 May 5; 117(18):4701-5. Epub 2011 Feb 03.
    View PubMed
  37. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011 Feb; 152(4):367-79. Epub 2011 Jan 10.
    View PubMed
  38. Paulus A, Swaika A, Miller KC, Spangenthal EJ, Guo R, Vonfricken K, Lee K, Chanan-Khan AA. Clinical relapse in a patient with multiple myeloma presenting as an atrial plasmacytoma. J Clin Oncol. 2011 Jan 20; 29(3):e47-9. Epub 2010 Oct 18.
    View PubMed
  39. Masood A, Sher T, Paulus A, Miller KC, Chitta KS, Chanan-Khan A. Targeted treatment for chronic lymphocytic leukemia. Onco Targets Ther. 2011; 4:169-83. Epub 2011 Nov 04.
    View PubMed
  40. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010 Nov 20; 28(33):4976-84. Epub 2010 Oct 18.
    View PubMed
  41. Chanan-Khan AA, Borrello I, Lee KP, Reece DE. Development of target-specific treatments in multiple myeloma. Br J Haematol. 2010 Oct; 151(1):3-15. Epub 2010 Jul 07.
    View PubMed
  42. Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG, International Myeloma Working Group. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia. 2010 Oct; 24(10):1700-12. Epub 2010 Sep 02.
    View PubMed
  43. Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, Messina M, Mitsiades CS, Anderson KC. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol. 2010 Aug; 150(4):438-45. Epub 2010 Jul 07.
    View PubMed
  44. Miller KC, Musial L, Whitworth A, Chanan-Khan A. Management of patients with chronic lymphocytic leukemia treated with lenalidomide. Clin J Oncol Nurs. 2010 Aug; 14(4):491-9.
    View PubMed
  45. Ciesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, Chanan-Khan A, Fenstermaker RA. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother. 2010 Aug; 59(8):1211-21. Epub 2010 Apr 27.
    View PubMed
  46. Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A. Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol. 2010 Aug; 150(4):418-27.
    View PubMed
  47. Baz R, Patel M, Finley-Oliver E, Lebovic D, Hussein MA, Miller KC, Wood M, Sher T, Lee K, Chanan-Khan AA. Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leuk Lymphoma. 2010 Jun; 51(6):1015-9.
    View PubMed
  48. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010 May 20; 28(15):2612-24. Epub 2010 Apr 12.
    View PubMed
  49. Ailawadhi S, Masood A, Sher T, Miller KC, Wood M, Lee K, Chanan-Khan A. Treatment options for multiple myeloma patients with high-risk disease. Med Oncol. 2010 Apr 14. [Epub ahead of print]
    View PubMed
  50. Ailawadhi S, Abdelhalim AN, Derby L, Mashtare TL, Miller KC, Wilding GE, Alberico RA, Gottlieb R, Klippenstein DL, Lee K, Chanan-Khan AA. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. Cancer. 2010 Jan 1; 116(1):84-92.
    View PubMed
  51. Sher T, Miller KC, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman MS, Miller A, Lawrence W, Bilgrami SA, Sood R, Wood MT, Block AW, Lee K, Chanan-Khan AA. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma. 2010 Jan; 51(1):85-8.
    View PubMed
  52. Ling X, Calinski D, Chanan-Khan AA, Zhou M, Li F. Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J Exp Clin Cancer Res. 2010; 29:8. Epub 2010 Jan 22.
    View PubMed
  53. Chanan-Khan A, Musial L, Miller KC, Lawrence D, Whitworth A, Padmanabhan S, Wilding GE, Ailawadhi S, Patel M, Sher T, Bangia N, Zeldis JB, Bilgrami S, Czuczman MS, Wallace PK, Desai S, Lee K. Lenalidomide-Associated Tumor Flare Reaction in Patients with Chronic Lymphocytic Leukemia. Cancer. 2010.
  54. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):908-42.
  55. Chanan-Khan A, Miller KC, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, Czuczman MS. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma. 2009 Jul; 50(7):1096-101.
    View PubMed
  56. Patel MP, Chanan-Khan AA. The many lives of thalidomide. Leuk Lymphoma. 2009; 50(6):861-2.
  57. Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Callander N, Lister J, Oken M, Jaganath S. Phase III randomized study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma. 2009; 50(4):559-65.
  58. Sher T, Miller K, Lee K, Chanan-Khan A. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report. Clin Lymphoma Myeloma. 2009; 9(4):328-30.
  59. Richardson PG, Xie W, Mitsiades CS, Chanan-Khan A, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter D, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi N, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato A. Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009; 27(21):3518-25.
  60. Patel MP, Masood A, Patel PS, Chanan-Khan AA. Targeting the Bcl-2. Curr Opin Oncol. 2009; 21:516-523.
  61. O’Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan A, Seymour JF, Gribben J, Itri LM, Rai KR. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized phase 3 trial of fludarabine plus cyclophosphamide with our without oblimersen: the Oblimersen CLL Study Group. J Clin Oncol. 2009; 27(31):5208-12.
  62. Ghoshal P, Nganga A, Moran-Giuati J, Szafranek A, Johnson T, Bigelow A, Houde C, avet- Loiseau H, Smiraglia D, Chanan-Khan A, Coignet L. Loss of the SMRT/NCoR2 co-repressor correlates with JAG2 over-expression in multiple myeloma. Cancer Res. 2009; 69(10):4380-7.
  63. Chanan-Khan AA, Sonneveld P, Harousseau JL, Richardson PG. Reply to C.A. Dasanu et al. J Clin Oncol. 2008 Oct 10; 26(29):4784-90.
  64. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Onc. 2008; 26(9):1544-52.
  65. Chanan-Khan AA, Whitworth A, Bangia N, Porter CW, Lee K. Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008; 26(9):4851-2.
  66. Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Neuwirth R, Anderson KC, Richardson PG. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008; 26:4784-90.
  67. Rodgers GM 3rd, Becker PS, Bennett CL, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Djulbegovic B, Garst JL, Gilreath JA, Kraut EH, Lin WC, Matulonis U, Millenson M, Reinke D, Rosenthal J, Sabbatini P, Schwartz RN, Stein RS, Vig R: National C Cancer-and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2008; 6:536-64.
  68. Manochakian R, Miller KC, Chanan-Khan AA. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Oncologist. 2007 Aug; 12(8):978-90.
    View PubMed
  69. Chanan-Khan. New treatments for chronic lymphocytic leukemia. Curr Oncol Rep 9 (5) 353-360. 2007; 9(5):353-360.
  70. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer E, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Patin J, Yu Z, Olesnyckyj M, Zeldis J, Knight R. Randomized, Phase III, Placebo-Controlled Trial of Lenalidomide in Combination With High- Dose Dexamethasone for Relapsed or Primary Refractory Multiple Myeloma. N Engl J Med. 2007; 357(21):2133-42.
  71. Chanan-Khan A, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007; 109(6):2604-6.
  72. Manochakian R, Miller KC, Chanan-Khan A. Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma. Clin Lymphoma Myeloma. 2007; 7(4):266-71.
  73. O'Brien S, Moore JO, Boyd TE, Larratt, LM, Skotnicki, A, Koziner, B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR, et al. Randomized Phase 3 Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 Antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2007; 25(9):1114-20.
  74. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yaholom J, Yunus F, National Compreh Multiple Myeloma: Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007; 5(3):118-147.
  75. Chanan-Khan A, Lee K. Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience. Clin Lymphoma. 2007; 48(6):1228-30.
  76. Reddy N, Karampelas I, Chanan-Khan A, Fenstermaker R, Padmanabhan S. Aggressive relapse of multiple myeloma with intracerebral extension and associated hemorrhage. Leu Lymph. 2007; 48(6):1228-30.
  77. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo D, Bennett MK, van Leeuwen, FW, Chanan-Khan AA, Orlowski RZ. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma. Blood. 2007; 110(9):3281-90.
  78. Moysich KB, Bonner MR, Beehler GP, Marshall JR, Menezes RJ, Baker JA, Weiss JR, Chanan-Khan A. Regular analgesic use and risk of multiple myeloma. Leuk Res. 2007; 31(4):547-51.
  79. Chanan-Khan A, Miller, KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006; 24(34):5343-9.
  80. O’Connor OA, Smith EA, Toner LE, Teruyda-Feldstein J, Frankel S, Rolfe M, Wei X, Liu S, Marcucci G, Chan KK, Chanan-Khan A. The combination of the proteasome inhibitor Bortezomib and the Bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res. 2006; 12(9):2902-11.
  81. Chanan-Khan A, Porter C. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol. 2006; 7:480-8.
  82. Chanan-Khan A, Miller KC. Supportive care in multiple myeloma. Clin Lymphoma Myeloma. 2006; 7(1):42-50.
  83. Miller KC, Padmanabhan S, DiMicelli L, DePaolo D, Landrigan B, Yu J, Doran, Marshal P, Chanan-Khan A. Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma. 2006; 47(11):2339-43.
  84. Scarpace S, Hahn T, Roy H, Brown K, Paplham P, Chanan-Khan A, van Besien K, McCarthy Jr P. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma. 2005; 46(2):239-42.
  85. Chanan-Khan A, Holkova B, Goldenberg AS, Pavlic A, Demopoulos R, Takeshita K. Non-Hodgkin’s lymphoma presenting as a breast mass in patients with HIV infection: A Report of three cases. Leuk Lymphoma. 2005; 46(8):1189-93.
  86. Chanan-Khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP, Mohr A, Klippenstein D, Wallace P, Zeldis JB, Berger C, Czuczman MS. Results of a phase I clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment - requiring chronic lymphocytic leukemia (CLL). Blood. 2005; 106:3348-52.
  87. Rodgers GM, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Demetri GD, Djulbegovic B, Garst JL, Gore M, Kraut EH, Lin WC, Millenson M, Mock V, Reinke D, Rosenthal J, Sabbatini P. Cancer- and treatment-related anemia. J Nat Compr Canc Netw. 2005; 3(6):773-89.
  88. Chanan-Khan A. Bcl-2 Antisense Therapy in B-cell Malignancies. Blood Reviews. 2005; 19(4):213-21.
  89. Czuczman MS, Fallon A, Stewart C, Donohue K, Blumerson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri FJ, Skippe M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005; 23(4):694-704.
  90. Chanan-Khan A. Bcl-2 antisense therapy in hematologic malignancies. Curr Opin Oncol. 2004 Nov; 16(6):581-5.
    View PubMed
  91. Ramanarayanan J, Hernandez-Ilizaliturri F, Chanan-Khan A, Czuczman M. Pro-apoptotic therapy with the oligonucleotide Genasense(tm) (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumor activity of rituximab. British Journal ofHematology. 2004; 127(5):519-530.
  92. Chanan-Khan A, Islam T, Alam A, Miller KC, Gibbs J, Barcos M, Czuczman MS, Paplham P, Hahn T, McCarthy P. Long-term survival with allogeneic stem cell transplant following salvage therapy with anti-CD 52 monoclonal antibody (Campath®) in a patient with α/β hepatosplenic Tcell non-Hodgkin’s lymphoma. Leukemia & Lymphoma. 2004; 45(8):1673-5.
  93. Chanan-Khan A, Sirinivasan S, Czuczman MS. Prevention and management of cardiotoxicity from antineoplastic therapy. Journal of Supportive Oncology. 2004; 2(3):251-6.
  94. Srinivasan S, Takeshita K, Holkova B, Czuczman MS, Bernstein ZP, Miller K, Driscoll D, Chanan-Khan A. Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of highly active antiretroviral therapy (HAART). HIV Clinical Trials. 2004; 5(3):140-5.
  95. Chanan-Khan A, Czuczman MS. Bcl-2 Antisense Therapy in B-cell Malignant Proliferative Disorders. Current Treatment Options in Oncology. 2004; 5(4):261-7.
  96. Chanan-Khan A. Bcl-2 Antisense Therapy in the Treatment of Multiple Myeloma. Oncology. 2004; 18(13 suppl 10):21-4.
  97. Hahn T, Rondeau C, Shaukat A, Jupudy V, Miller A, Alam AR, Baer MR, Bambach B, Bernstein Z, Chanan-Khan AA, Czuczman MS, Slack J, Wetzler M, Mookerjee BK, Silva J, McCarthy PL Jr. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant. 2003 Aug; 32(4):405-10.
    View PubMed
  98. Chanan-Khan A, Holkova B, Perle MA, Reich E, Wu CD, Takeshita K. T-cell clonality and myelodysplasia without chromosomal fragility in a patient with features of Seckel syndrome. Haematologica. 2003; 88(05):ECR14.
  99. Benekli M, Hahn T, Shafi F, Qureshi A, Alam AR, Czuczman MS, Bernstein ZP, Chanan-Khan AA, Becker JL, McCarthy PL. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin’s lymphoma patients. Bone Marrow Transplant. 2003; 32(2):139-43.
  100. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, Muggia FM. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Annals of Oncology. 2003; 14(9):1430-7.
  101. Bernstein ZP, Chanan-Khan A, Miller KC, Northfelt DW, Lopez-Berestein G, Gill PS. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Cancer. 2002 Dec 15; 95(12):2555-61.
    View PubMed
  102. Ahmad I, Islam T, Chanan-Khan A, Hahn T, Wentling D, Becker J, McCarthy P, Alam A. Thalidomide as salvage therapy for VAD-refractory multiple myeloma patients prior to autologous PBSCT. Bone Marrow Transplant. 2002; 29:577-80.
  103. Bernstein ZP, Brooks SP, Chanan-Khan A, Gollnick SO, Gilbert MJ, Tomasi TB. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Restores Allostimulatory Function to Accessory Cells in Patients with AIDS. HIV Clinical Trials. 2002; 3(3):219-24.
  104. Szebeni J, Baranyi L, Savay S, Milosevits J, Bunger R, Laverman P, Metselaar JM, Storm G, Chanan-Khan A, Liebes L, Muggia FM, Cohen R, Barenholz Y, Alving, CR. Role of complement activation in hypersensitivity reactions to Doxil and Hynic PEG Liposomes: Experimental and clinical studies J of Liposome Research. 2002; 12:165-72.
  105. Chanan-Khan A, Czuczman MS. Radioimmunotherapy in non-Hodgkin’s lymphoma. Curr Opin Oncol. 2002; 14:484-9.
  106. Holkova B, Takeshita K, Cheng DM, Volm M, Wasserheit C, Demopoulos R, Chanan-Khan A. Effect of highly active antiretroviral therapy on survival in patients with AIDSassociated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol. 2001; 19(18):3848-51.